| Keywords: |
survival; adult; cancer chemotherapy; cancer survival; preschool child; treatment outcome; child, preschool; survival analysis; survival rate; gene mutation; promoter region; genetics; clinical trial; cancer combination chemotherapy; risk benefit analysis; side effect; treatment planning; note; cancer radiotherapy; chemotherapy, adjuvant; temozolomide; brain tumor; brain neoplasms; antineoplastic agent; treatment indication; medical decision making; dacarbazine; antineoplastic combined chemotherapy protocols; editorial; alkylating agent; systematic review; adjuvant chemotherapy; glioblastoma; medulloblastoma; antineoplastic agents, alkylating; drug derivative; gene silencing; methylated dna protein cysteine methyltransferase; cerebellar neoplasms; meta analysis; nitrosourea derivative; cerebellum tumor; o(6)-methylguanine-dna methyltransferase
|
